Scholarlink

Objective <p>mTOR is involved in the pathogenesis of Graves’ orbitopathy (GO). Because mTOR can be detected in the bloodstream, we postulated that serum mTOR could be associated with GO. Thus, we evaluated serum mTOR in GO.</p> Methods <p>mTOR was measured by ELISA in serum samples from 77 consecutive patients with Graves’ hyperthyroidism (GH), 57 of whom with GO and in 19 healthy subjects. The primary endpoint was serum mTOR in GH patients with GO vs GH patients without GO.</p> Results <p>Median serum mTOR was 2440 pg/ml (1236–3053) in GO patients, 1236 pg/ml (388.5–1770) in GH without GO, and 247 pg/ml (0.9–705) in healthy subjects. mTOR was greater in GH than in healthy subjects (P=0.00012), and, within GH, in patients with GO (P = 0.0023). In GO patients, there was a direct correlation between mTOR and the clinical activity score (R = 0.377; P = 0.0038) and mTOR was higher in moderate-to-severe than in mild GO (P = 0.016). We established a cut-off value of 1445.8 pg/ml of serum mTOR (97th percentile in healthy subjects) that distinguished GO patients within GH [positive predictive value (PPV): 79.2%; sensitivity: 73.6%; specificity: 55%].</p> Conclusions <p>Serum mTOR is associated with GH, in particular with the presence, activity and severity of GO. Additional studies are required to determine whether serum mTOR can be used as a biomarker in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum mTOR: an associative marker of Graves’ orbitopathy

  • 期刊论文

  • 发表日期：

    2026年3月25日

查看全文
  • Giulia Lanzolla,
  • Giovanna Rotondo Dottore,
  • Simone Comi,
  • Giada Cosentino,
  • Maria Novella Maglionico,
  • Chiara Posarelli,
  • Dalì Antonia Ciampa,
  • Gaia Chiapparelli,
  • Francesca Menconi,
  • Michele Figus,
  • Ferruccio Santini,
  • Michele Marinò

摘要

Objective

mTOR is involved in the pathogenesis of Graves’ orbitopathy (GO). Because mTOR can be detected in the bloodstream, we postulated that serum mTOR could be associated with GO. Thus, we evaluated serum mTOR in GO.

Methods

mTOR was measured by ELISA in serum samples from 77 consecutive patients with Graves’ hyperthyroidism (GH), 57 of whom with GO and in 19 healthy subjects. The primary endpoint was serum mTOR in GH patients with GO vs GH patients without GO.

Results

Median serum mTOR was 2440 pg/ml (1236–3053) in GO patients, 1236 pg/ml (388.5–1770) in GH without GO, and 247 pg/ml (0.9–705) in healthy subjects. mTOR was greater in GH than in healthy subjects (P=0.00012), and, within GH, in patients with GO (P = 0.0023). In GO patients, there was a direct correlation between mTOR and the clinical activity score (R = 0.377; P = 0.0038) and mTOR was higher in moderate-to-severe than in mild GO (P = 0.016). We established a cut-off value of 1445.8 pg/ml of serum mTOR (97th percentile in healthy subjects) that distinguished GO patients within GH [positive predictive value (PPV): 79.2%; sensitivity: 73.6%; specificity: 55%].

Conclusions

Serum mTOR is associated with GH, in particular with the presence, activity and severity of GO. Additional studies are required to determine whether serum mTOR can be used as a biomarker in clinical practice.